Actinium Pharmaceuticals, Inc.

NYSEAM:ATNM Stock Report

Market Cap: US$55.5m

Actinium Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Actinium Pharmaceuticals's earnings have been declining at an average annual rate of -19.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 11.4% per year.

Key information

-19.5%

Earnings growth rate

28.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate11.4%
Return on equity-97.2%
Net Margin-52,621.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28
Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Revenue & Expenses Breakdown

How Actinium Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSEAM:ATNM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-431235
31 Mar 240-461337
31 Dec 230-491339
30 Sep 230-501538
30 Jun 230-461533
31 Mar 230-391427
31 Dec 221-331223
30 Sep 221-301121
30 Jun 221-271019
31 Mar 221-25818
31 Dec 211-25818
30 Sep 211-23717
30 Jun 211-22716
31 Mar 211-22616
31 Dec 200-22616
30 Sep 200-20615
30 Jun 200-21616
31 Mar 200-22616
31 Dec 190-22617
30 Sep 190-24618
30 Jun 190-23618
31 Mar 190-23617
31 Dec 180-24717
30 Sep 180-22716
30 Jun 180-23716
31 Mar 180-25818
31 Dec 170-27918
30 Sep 170-281018
30 Jun 170-281019
31 Mar 170-281019
31 Dec 160-24918
30 Sep 160-24916
30 Jun 160-22913
31 Mar 160-221013
31 Dec 150-211114
30 Sep 150-201215
30 Jun 150-221316
31 Mar 150-111115
31 Dec 140-251012
30 Sep 140-2589
30 Jun 140-2065
31 Mar 140-2754

Quality Earnings: ATNM is currently unprofitable.

Growing Profit Margin: ATNM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ATNM is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.

Accelerating Growth: Unable to compare ATNM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATNM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15%).


Return on Equity

High ROE: ATNM has a negative Return on Equity (-97.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies